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Abstract 
Background and purpose 
We aim to report on local control in a phase II trial on preoperative hyperfractionated and 
accelerated radiotherapy schedule (HART) in locally advanced resectable rectal cancer 
(LARC). This fractionation schedule was designed to keep the overall treatment time (OTT) 
as short as possible. 
Patients and methods 
This is a prospective trial on patients with UICC stages II and III rectal cancer. The patients 
were submitted to a total dose of 41.6 Gy, delivered in 2.5 weeks at 1.6 Gy per fraction twice 
a day with a 6-h interfraction interval. Surgery was performed within 1 week after the end of 
irradiation. Adjuvant chemotherapy was delivered in a subset of patients. 
Results 
Two hundred and seventy nine patients were entered and 250 are fully assessable, with a 
median follow-up of 39 months. The 5-years actuarial local control (LC) rate is 91.7%. The 
overall survival (OS) is 59.6%. The freedom from disease relapse (FDR) is 71.5%. 
Downstaging was observed in 38% of the tumors. 
Conclusion 
The actuarial LC at 5 years is 91.7%, although we are dealing with stages II–III LARC, 
mainly located in the lower rectum (median distance=5 cm). The pattern of failure is 
dominated by distant metastases and treatment intensification will obviously require a 
systemic approach. 
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In Europe, in contrast to the United States and Canada, a preoperative approach has been 
considered as the preferred treatment option for locally advanced rectal cancer (LARC) to 
reduce the incidence of local recurrence. This European option is based on the knowledge that 
irradiation before surgery is more dose-effective and cost-effective than postoperative 
irradiation and in general less toxic [11], [16], [19], [37] and [48]. 
Even if there is a major decrease in the rate of local recurrences, especially if surgeons are 
instructed to replace the blunt dissection with a sharp dissection of the mesorectum, there is 
little doubt about the requirement for radiotherapy at least in the preoperative setting [6] and 
[9]. This has been confirmed by the results of the Swedish rectal cancer trial (SRCT) and the 
Dutch colorectal cancer group trial (DCRCG) [24] and [47]. 
However, there is no consensus amongst the published literature about what should be the 
‘standard’ treatment and the primary endpoint in rectal cancer (survival, disease free survival, 
local control, sphincter sparing surgery or quality of life). 
To date, the only trial showing a significant impact of radiotherapy alone on LC and OS is the 
SRCT [47]. The positive impact on LC by the five consecutive 5 Gy of pelvic radiation 
therapy, as used in the SRCT, has been recently confirmed by the Dutch colorectal cancer 
group trial (DCRCG) [24]. In the latter study, the follow-up is too short to determine the 
impact of this approach on OS. 
In the EORTC 22921 (European Organization Research Treatment Cancer) and FFCD 9203 
(Fondation Française de Cancérologie Digestive) trials, in contrast to the SRCT and the 
DCRCG, a ‘conventional’ preoperative fractionation and total dose of radiotherapy (45 Gy in 
25 fractions) and timing of surgery (i.e. a gap of at least 4 weeks after neo-adjuvant treatment) 
have been used [1] and [14]. In the EORTC 22921, the local failure rate has been reduced in 
the three groups with chemotherapy (8.8% preoperative radio-chemotherapy, 9.6% 
preoperative radiotherapy and postoperative chemotherapy, 8.0% preoperative radio-
chemotherapy and postoperative chemotherapy) [1]. The results do not indicate the best 
timing and do not suggest a benefit for the combined use of preoperative and postoperative 
chemotherapy. 
It is obvious that if OS and DFS are the primary endpoints, emphasis should be put on the 
development of systemic treatment and optimization of its use [17]. Both the EORTC-22921 
trial and the FFCD 9203 trial do not show an impact of chemotherapy on overall survival 
(OS) or progression free survival (PFS)[1] and [14]. Moreover, in the FFCD 9203 the 
sphincter preservation rate is not increased [14]. 
The German intergroup study, a randomized study comparing postoperative radio-
chemotherapy to preoperative radio-chemotherapy, demonstrates an advantage in local 
control in favor of the latter and hence reinforces a neo-adjuvant approach and the choices 
made in both the ECOG 3201 and the NSABP R-04 trials [42]. In these trials, there is no 
postoperative radiotherapy arm anymore, illustrating a change in paradigm in the United 
States and Canada where postoperative radiotherapy combined with chemotherapy is the most 
frequently used approach [34]. 
As no radiotherapy schedule can be considered ‘standard’, we intend to report our own results 
on HART. HART was designed to keep the overall treatment time (OTT) as short as possible 
without using hypo-fractionation as in the SRCT and DCRCG trials. We decided to use a 
twice a day accelerated hyper-fractionated schedule. Theoretical calculations using the linear 
quadratic model, yielded a potential benefit of 13–29% in anti-tumor effect (α/β=10 Gy) and a 
theoretical reduction of 4% in late toxicity (α/β=3 Gy) (see Table 1). 
Table 1.  








Lag period 0 days 35 39.8 1.14 
(*) 32.5 37.3 1.15 
Lag period 5 days 37.5 42.3 1.13 
(*) 35 39.8 1.13 
Lag period 10 days 37.5 44.8 1.19 
(*) 37.5 42.3 1.13 
No repopulation 37.5 48.3 1.29 
BED=biological effective dose=[physical dose×(relative effect)]−[0.5 Gy/day×(OTTR−lag)]. 
OTTR is the overall treatment duration in days of the preoperative irradiation. Relative 
effect=1+d/α/β. The lag period is defined as the period before which there is no any dose 
compensation necessary to counteract proliferation. Lag period=0 days means immediate 
repopulation. Following assumptions were made for calculation: (1) a dose increment of about 
0.5 Gy per day of radiation treatment extension is required to compensate for rapid growth 
[46]; (2) the gap (=time delay) between the end of the five times 5 Gy and the surgery (SRCT 
and DCRCG) is of the same magnitude as the one observed in the HART 93-01 trial. The 
decrease of biological effect would be similar and therefore not accounted for in the 
calculation; (3) the gap between end of radiotherapy and surgery is accounted for in the 
calculation of BED values. See (*). 
 
 
As a possible decrease of 4% in late complications is not easy to highlight, our primary aim 
was to evaluate the impact of HART on LC. 
1. Materials and methods 
1.1. Patient population 
This trial was conducted from 1993 to 2002 at two radiation oncology centers, Lausanne (LS) 
and Aarau (AA), and was approved by the Human Investigations Committee at both centers. 
All patients with LARC were treated on protocol after obtaining informed consent for 
treatment. We considered a target of 250 eligible patients in order to have an appropriate 
estimation of the effect of HART on local control. 
All those patients underwent a complete clinical examination, a chest X-ray, together with an 
abdomino-pelvic computed tomography (CT), a transrectal ultrasound (TRUS), a complete 
colonoscopy and a thorough digital rectal examination (DRE) by the attending radiation 
oncologist. All tumors were confirmed to be malignant on biopsy. Patients were deemed 
eligible for Trial 93-01 if they presented with clinical stage T3–T4 or in T1–T2 rectal cancer 
provided that in the latter cases, there was compelling evidence for clinical and/or radiological 
nodal invasion (TNM classification of malignant tumors) [44]. The criteria for T4 disease 
were evidence of adjacent organ invasion on CT or TRUS. The level of the tumor within the 
rectum was measured from the anal verge with a rigid sigmoidoscope and checked at DRE by 
the radiation oncologist. The maximal allowed distance to the anal margin was 15 cm. 
Laboratory studies included estimation of pretreatment complete blood count, liver and 
kidney function and CEA-level. 
Exclusion criteria included any of the following: no informed consent, age younger than 18 
years, ECOG performance status of 4 [35], pregnant or lactating women, prior pelvic 
irradiation therapy, treatment with chemotherapy prior to the initiation of radiotherapy, other 
malignant tumor history, or any other serious illness and/or major organ dysfunction that 
could potentially preclude the feasibility of the preoperative radiotherapy followed by surgery 
with curative intent. There was no upper age limit in this trial. 
1.2. Treatment characteristics 
A detailed description of the treatment technique has been previously published [7] and [8]. 
All patients received preoperative pelvic irradiation in prone position. The treatment was 
given with a linear accelerator with a minimum energy of 6 MV through a four field 
technique with every field irradiated twice daily. The schedule consisted of a total dose of 
41.6 Gy applied in 1.6 Gy twice a day with a 6 h free interval between the fractions. The 
overall treatment time including the weekends counted 17 days (no treatment on Saturday and 
Sunday). 
The dose prescription was done at the intersection of the four fields. The requirement for dose 
homogeneity were a planning target volume (PTV) covered at least by the 95% isodose 
(lower limit), with an upper limit set at 110%. 
No radiation therapy was performed after surgery, even if the radial resection margin (RRM) 
was positive (i.e. an R1=microscopic invasion or R2=macroscopic invasion) on pathological 
specimen. Radiation therapy was never given after surgery to avoid the increased risk of late 
complications [27] and [43]. 
1.3. Surgical procedure, postoperative chemotherapy 
The protocol required surgery within 1 week of completion of radiotherapy. The surgeons 
were asked to perform a total mesorectal excision (TME) with a sharp dissection for distally 
located tumors and a partial mesorectal excision for tumors in the upper third of the rectum 
[20], [21] and [28]. However, no quality control could be performed on the surgical 
procedure. The decision to perform a low anterior resection (LAR) vs an abdominoperinal 
resection (APR) was left to the discretion of the individual surgeon. In case an attempt was 
made to perform a SSP, we suggested a temporary diverting colostomy. If an SSP was 
performed, the protocol suggested a colorectal or coloanal anastomosis with reconstruction of 
a reservoir function (colonic pouch). Postoperative chemotherapy was performed in selected 
patients (essentially in case of ypN+). 
1.4. Pathology review 
All records from one single reference center (LS) (N=136), were systematically submitted to 
an extensive quality control by the attending study pathologist (HB) according to the 
methodology described by Quirke [38], [39] and [40]. These data were already published in 
part elsewhere [2], [3] and [4]. For the remaining a central pathology review was not 
performed because of economic and logistical difficulties. In the present analysis we decided 
to include following factors: tumor differentiation, tumor stage (both T-stage and N-stage), 
downstaging (ypT<cT and not to be confounded with downsizing), resection margins and 
especially RRM and clearance (defined as the distance between the peripheral tumor rim and 
the radial resection margin). 
1.5. Follow-up of patients 
All patients were followed prospectively every 3 months the first year and every 6 months 
thereafter. At follow-up patient history has been recorded and a physical examination was 
systematically performed. This was completed by a test for CEA and a TRUS if patient were 
submitted to a SSP. If not, this TRUS was replaced by an abdominal and pelvic CT-scan 
every 6 months for 2 years and yearly thereafter. If they did not present at their bi-annual 
exam, a phone call was given to the general practitioner in charge of this patient or directly to 
the patient to recover the necessary information. Every failure, whether it was the primary 
failure or not, was recorded and verified by reviewing the multidisciplinary medical records. 
1.6. Statistical analysis 
Statistical analysis was performed with JMP 5.0 (from SAS Institute, Inc., Cary, NC, USA) 
on a Powerbook G4. Outcome estimates were calculated with the product limit survival 
method. 
For local control, only recurrence within the irradiated pelvis was scored as an event. Local 
recurrence was defined as any evidence of tumor within the surgical bed and the volume 
encompassed by the radiation fields (PTV). Every failure outside the PTV, whether 
abdominal or extra-abdominal, was defined as a distant failure (metastatic disease). 
OS was calculated from the initiation of the radiation treatment until death, whatever the 
reason of death. Freedom from disease relapse (FDR) has been calculated considering local 
recurrence, distant failure and death due to cancer as an event. Therefore, patients dying from 
unrelated causes were not added to treatment failures. 
Grouping was generally performed on the basis of the median value for quantitative data (if 
not this is specified). A two-sided Log-Rank test was used to assess statistical significance of 
the difference between strata. A difference between curves was considered significant if a P-
value of ≤0.05 was reached. We used a Willcoxon test for evaluating a difference between 
two survival curves, provided these curves are initially dissociating but rejoining at a given 
time point later. Factors reaching a P-value of P≤0.05 in the univariate analysis (Log-Rank 
test), were introduced in the Cox proportional hazard model. Before doing so we used a non-
parametric Spearman's rank correlation test (assuming that for some parameters the 
distribution is not necessarily Gaussian) to test for correlations between parameters. This 
allowed us to check for multicolinearity between parameters. We tested in the multivariate 
model whether substitution for example of cT and ypT or vice versa did modify the final 
model, as both were likely to act as surrogates for disease control. 
2. Results 
2.1. Characteristics of patient population and treatment 
Two hundred and seventy nine patients with LARC were enrolled on Trial 93-01 from 1993 
to 2002. Twenty-four patients were excluded as they presented with liver metastasis at 
surgery (treatment considered palliative) and five because of missing surgical and/or 
pathological data and/or because of missing follow-up. Of the remaining 250 patients, there 
were 164 males and 86 females. 
The median follow-up for all patients is 39 months and for surviving patients 52 months. 
The median pretreatment CEA level was 3.1 ng/ml (normal value ≤5 ng/ml). There were only 
four patients presenting with cT2, but with a clear clinical (at DRE a para-rectal node was 
discovered in two cases) and/or radiological suspicion (TRUS and/or CT) of nodal disease. 
There were 201 cT3 patients and 45 cT4. The median distance to the anal verge was 5 cm 
(mean 5.6±0.2 cm, range 0–15 cm). At DRE the tumor is considered ‘tethered’ or ‘fixed’ in 
196 patients (78%). Fixed tumors are not considered cT4 except if there is a radiological 
suspicion (TRUS or CT). The rectal tumor has been labelled ‘mobile’ in 25 patients (10%). 
This clinically retrievable information was not available in 29 patients. 
All patients received radiation therapy as per the protocol. There were no treatment 
interruptions for acute toxicity. The only interruptions recorded were due to holidays or 
engine downtime. The maximal treatment duration registered for one single patient was 22 
days due to misunderstanding of the protocol. The gap between the end of the radiation 
therapy and the surgery was per protocol (median=5 days; range: 1–120 days; 75th 
percentile=7 days, 90th percentile=12 days, 10th percentile=2 days). 
In total, there were 23 surgical departments participating to this trial. Due to the large number 
of surgical departments and the number of surgeons per department in the present trial, the 
mean number of patients per surgeon is low. This has to be considered as a major risk factor 
for local recurrence [22], [25], [32], [38] and [41]. 
A majority of patients (N=141) underwent an SSP (56.4%). On the 250 patients there were 
109 APR, 137, LAR, three Hartman procedures and one transanal resection. Most of the 
tumors were located in the middle and lower third of the rectum. In 133 patients the distance 
to the anal margin was ≤5 cm and in 37 of these patients an SSP was performed (28%). In 
only 7 out of 76 patients an SSP was attempted when the lower end of the tumor was located 
at ≤3 cm from the anal margin. 
At pathological examination there were 21 ypT4 (8.4%), 161 ypT3 (64.4%), 57 ypT2 
(22.8%), 8 ypT1 (3.2%) and finally three complete responses ypT0 (1.2%). Comparing ypT to 
cT yielded a downstaging rate of 38%. One hundred and eighteen patients (47%) had positive 
nodes at pathological examination. The median number of nodes retrieved by the pathologist 
on the specimens was 13. Vascular invasion was observed in 57 cases and was absent in 189 
patients (information was not available in four). In 44 cases a resection margin was positive 
(18%). In three patients out of these 44, the margin involved was not the circumferential but 
the distal margin. Eighty patients (32%) received 5-FU based adjuvant chemotherapy because 
positive lymph nodes were detected on surgical specimens. 
2.2. Local control, survival and freedom from disease relapse 
The actuarial local control (LC) at 5 years is 91.7±0.02% (patients at risk at 5 years=70). Only 
16 patients failed locally. The median for LC is not reached (Fig. 1A). The actuarial 5-years 
overall survival (OS) is 59.6±3.7% (number of patients remaining at risk at 5 years=70). The 
median OS is not yet reached. The 5 years actuarial freedom from disease relapse (FDR) is 
71.5±3.5% (patients at risk at 5 years=70)(Fig. 1B). The median is not yet reached. 
 
 
Full-size image (9K) 
Fig. 1. (A) Actuarial local control as a function of time expressed in months; (B) actuarial 
freedom from disease relapse expressed in months after initiation of HART. 
 
 
2.3. Univariate analysis 
A variety of patient's and tumor related factors were tested in the univariate analysis for LC, 
OS and FDR. We report only on the results for local control in Table 2. The cut-off values for 
quantitative data (cov), are the median values, except for the lateral clearance where the value 
of 2 mm has been used [31] and [33]. 
Table 2.  

















Clinical T-stage T2–T3 vs T4 93.5 83.8 0.03 0.01 
Tumor thickness ≤8 mm 94.4 88.3 0.02 0.02 
Lateral clearance 2 mm 81.1 94.3 0.0006 0.0006 
Vascular invasion (VI) VI0 vs VI+ 93.2 86.6 0.10 0.07 
Microscopic complete 
resection R0 vs R1 94.1 80.7 0.07 0.03 
Not listed in the table of contents though tested are the following: gender, age, WHO status, 
CEA-level prior to treatment, assessment of clinical fixation, surgical procedure, axial and 
transverse tumor diameter, histological differentiation, pathological T-stage and N-stage, 
downstaging, and adjuvant chemotherapy. For all the other factors a difference is considered 
significant if a P≤0.05 is reached. Only those factors reaching a P≤0.05 with the Log-Rank 
test are considered for the proportional hazards model. 
 
 
2.4. Multivariate analysis 
For the multivariate analysis (proportional hazards model), only those factors reaching a 
P≤0.05 in the univariate analysis (Log-Rank) were selected (see Table 3). This yielded in the 
final model a better OS for patients aged less than 64, with ypN0 and VI0. The factors 
predictive for a better FDR were clinical T-stage less than cT4, ypN0 and VI0. Finally for LC, 
the only factor which was predictive for a better outcome is a clearance of more than 2 mm. 
Table 3.  
Multivariate analysis considering only factors issued from univariate analysis with a P-value 
of ≤0.05 (Log-Rank) 
Endpoint Discriminator P-value RR CI 
OS Age<64 0.03 0.78 0.62–0.97 
 ypN0 0.0006 0.67 0.52–0.84 
 VI0 0.006 0.72 0.57–0.91 
FDR Stage<cT4 0.04 0.73 0.55–0.98 
 ypN0 0.0004 0.59 0.43–0.79 
 VI0 0.01 0.69 0.52–0.92 
LC Clearance>2 mm 0.002 0.45 0.27–0.74 




Preoperative radiotherapy does reduce the risk of local recurrence in rectal cancer [6], [9], 
[13], [24] and [48]. If the concept of preoperative radiotherapy seems to be widely accepted 
nowadays, there is still a debate ongoing what should be considered as ‘standard’ total dose 
and fractionation [5] and [48]. Hypo-fractionation, i.e. five times 5 Gy applied in five 
consecutive days, has been extensively tested in Europe. The effect of this fractionation on 
local control observed for the first time in the Swedish rectal cancer trial (SRCT) have 
recently been confirmed by the investigators of the Dutch colorectal cancer group (DCRCG). 
It has been estimated that only 50% of the patients in the SRCT trial were submitted to a ‘lege 
artis’ TME [9]. Therefore, if one could initially doubt about the adequacy of the surgery in the 
SRCT, this argument is of no value for patients in the DCRCG-trial [24]. In this large recently 
published multicenter trial, special effort has been dedicated to optimizing and standardizing 
the TME procedure and training the surgeons [25]. 
There is no consensus on the duration of the interval (‘gap’) between the end of the 
radiotherapy and the surgery [12], [26], [29], [36], [45] and [48]. In the SRCT the surgery was 
generally performed immediately after the weekend following the end of the irradiation, 
whereas in the DCRCG trial the total duration of the radiotherapy and the gap to the surgery 
had to be contained within 10 days [24] and [47]. 
What are the arguments against hypofractionation? One might argue that the hypo-
fractionation is responsible for the high rate of postoperative complications reported by those 
groups (perineal complication rate after 5×5 Gy and APR=29% in the DCRCG) [10], [26] and 
[30]. On the other hand, the short interval between the radiotherapy and the surgery does not 
allow for a significant tumor downsizing considered as the primary endpoint by surgeons 
aiming at increasing the rate of SSP. Downstaging is also not obvious, but apparently this 
seems not a prerequisite for a better survival [18], [29] and [45]. 
If one considers a rapid schedule as a ‘standard’ (based on the absolute numbers of patients 
introduced in SRCT and DCRCG, compared to the limited data available for more 
‘conventional’ fractionation), there is still a debate ongoing on the necessity of hypo-
fractionation to obtain both an effect on local control and survival. 
In Lausanne we initiated in 1989 a modified fractionation schedule, initially in the 
postoperative setting after curative resection for LARC [7]. Aware of the advantage of using 
pre instead of postoperative radiotherapy, we decided to use this hyperfractionated accelerated 
radiotherapy in a neo-adjuvant setting, but lowering the total dose from 48 Gy in the 
postoperative setting to 41.6 Gy in the preoperative setting [8]. As in the SRCT, we decided to 
keep the interval between the radiotherapy and the surgery as short as possible (1 week 
suggested in the protocol outline). The feasibility of this HART approach in a preoperative 
setting has been published earlier [7] and [8]. As toxicity has been minimal in the phase I trial, 
we decided to prospectively accrue patients in two centers in order to evaluate the impact of 
HART especially on local control and eventually on OS and FDR. The calculation of the 
biological effectiveness of HART, both for tumor tissue (α/β=10 Gy) and healthy tissue 
(α/β=3 Gy), yields a theoretical advantage compared to the SRCT/DCRCG schedule. Local 
control could potentially be increased by 13–29%. The advantage in late toxicity is less 
obvious (4% reduction of late effects). Such a small difference in late complications will be 
difficult to highlight within a randomized controlled trial of a reasonable size. 
As we report our results with a median overall follow-up of 39 months, we can compare with 
the SRCT/DCRCG figures. However, in our non-randomized 93-01 Trial we have included 
only patients with resectable stages II and III disease (no stage I disease). For advanced 
inoperable rectal cancer we considered that other radiation techniques are more adequate [23]. 
There were only four patient with cT2, but for these patients there was a clear clinical and/or 
radiological suspicion of nodal involvement (cT2N+=stage II). All the other patients 
presented with cT3 (N=201) and cT4 tumors (N=45). Therefore we cannot directly compare 
our data with the DCRCG since up to 30% of patients had stage I tumors in the latter. 
There is another more fundamental reason why direct comparison with DCRCG data is 
difficult. In Trial 93-01 we are not able to define a posteriori whether lege artis TME with 
sharp dissection has been performed. There has been no quality control implemented nor 
training performed amongst the surgeons involved in this trial. We are agreeing that this is a 
major limitation in the interpretation of our data. On the other hand, the ‘negative’ selection of 
patients (low lying tumors, mostly tethered or fixed and no stage I) and the absence of quality 
control for surgery, illustrates the efficacy of the present fractionation schedule for obtaining 
good local control in LARC. The actuarial local recurrence rate at 2 years in Trial 93-01 is 
6.4%, compared to 2.4% in the DCRCG trial and 8.3% in the SRCT [24] and [47]. 
As the major event in our cohort is the appearance of distant metastases, it is obvious that one 
has to consider a treatment approach aiming at preventing and/or eradicating metastases. 
Therefore, our group has been running in parallel to Trial 93-01, Trial 98-02 in which we 
have been treating patients with LARC with HART and CPT-11. This Trial 98-02 is a pure 
phase I trial, and we are only able to report on feasibility [49]. However, adding 
chemotherapy to our HART schedule should remain experimental and performed within the 
strict limits of well designed clinical trials. 
How do our data compare with those from trials in which chemotherapy has been added? The 
German trial (CAO/ARO/AIO-94), shows that the 5-years pelvic recurrence rate is 6% for the 
preoperative combined chemo-radiotherapy compared to 13% for the postoperative combined 
treatment (P=0.006). Disease free survival and overall survival are similar (respectively 68 vs 
65% and 76 vs 74%; P-values not significant) [42]. The recently presented EORTC 22921 
trial concludes that adding chemotherapy to radiotherapy does not modify OS (ranging from 
64.8 to 67.1% compared to 63.2% if no chemotherapy at all) or progression free survival 
(ranging from 54.5 5 to 58.15 compared to 52.2%, respectively) [1]. There is a significant 
impact on local control (recurrence rate 8–9.6% vs 17.2%), but there is no indication on the 
best timing of the chemotherapy. The local control rate is the same if patients receive 
preoperative radiotherapy and postoperative chemotherapy. Moreover, there is no 
supplementary benefit if chemotherapy is applied both in the preoperative and postoperative 
setting. The FFCD 9203 randomized trial does not show an improvement in 5 year overall 
survival (66.6 vs 67.8%) if bolus 5-fluoro-uracil and folinic acid is added to preoperative 
irradiation. The sphincter preservation is identical in both arms (51.7 and 52.6%) [14]. 
In conclusion, taking into account the high risk patient group (stages II and III and low 
located tumors) and the lack of quality control for surgery, our rate of local control at 5 years 
(91.7%) as well as survival figures (OS 59.6% and FDR 71.5%) compare favorably with those 
issued from large randomized trials. Distant metastases are the most common site of failure. 
Hence, effective systemic chemotherapy combined or not to targeted agents given pre or 
postoperatively will be required to modify significantly OS or FDR [15] and [48]. 
 
